Sponsored by:

Molecular Imaging: Page 210

PET tracer boosts detection of recurrent prostate cancer
By AuntMinnie.com staff writers
A newly developed radiotracer significantly improves the early detection of recurrent prostate cancer, according to research published in the Journal of Nuclear Medicine.
September 17, 2015
EM Imaging signs with GE for cancer imaging agent
By AuntMinnie.com staff writers
Edinburgh Molecular Imaging (EM Imaging) has signed a global license agreement with GE Healthcare and Dyax for an optical imaging agent that could improve the detection of early-stage colorectal cancer.
September 16, 2015
CMS rejects broader payments for NaF-PET
By AuntMinnie.com staff writers
The U.S. Centers for Medicare and Medicaid Services (CMS) has rejected a proposal to loosen the restrictions on reimbursement for sodium fluoride (NaF) PET for detecting cancer that has metastasized to the bone.
September 16, 2015
Jubilant DraxImage, Cyclopharm ink deal
By AuntMinnie.com staff writers
Radiopharmaceutical firm Jubilant DraxImage has signed a term sheet for an exclusive license for U.S. marketing and distribution of Technegas, a lung imaging radiopharmaceutical from Australian firm Cyclopharm.
September 15, 2015
DEA removes GE compound as controlled substance
By AuntMinnie.com staff writers
The U.S. Drug Enforcement Administration (DEA) has removed a compound found in GE Healthcare's DaTscan SPECT radiopharmaceutical from the schedules of the Controlled Substances Act, which means the imaging agent will be more widely available to the medical community.
September 13, 2015
Nuclear medicine market to reach $2.13B by 2020
By AuntMinnie.com staff writers
The global nuclear medicine equipment market is expected to grow at a compound annual growth rate of 3.6% over the next five years, according to a new report by market research firm MarketsandMarkets.
September 10, 2015
NorthStar, Westinghouse Electric join forces
By AuntMinnie.com staff writers
With an eye toward increasing the worldwide supply of molybdenum, NorthStar Medical Radioisotopes and nuclear energy firm Westinghouse Electric have inked a memorandum of understanding to explore the potential of producing medical radioisotopes in commercial nuclear reactors.
September 8, 2015
PET/MRI can be a boon for pediatric cancer patients
By Wayne Forrest
Young pediatric patients may benefit from FDG-PET/MRI for staging and clinically evaluating oncologic disorders, given the hybrid modality's superior soft-tissue contrast and significantly lower radiation dose, according to a study published online August 24 in Investigative Radiology.
September 8, 2015
2015 09 09 08 37 15 557 Gatidis Petmri 450 20150909154729
U.S. NRC starts review of LNT radiation theory
By AuntMinnie.com staff writers
The U.S. Nuclear Regulatory Commission (NRC) is reviewing the linear no-threshold (LNT) model of the health effects of radiation and the idea that LNT should be replaced with a radiation hormesis model.
September 7, 2015
ImaginAb highlights prostate imaging trial
By AuntMinnie.com staff writers
Imaging agent developer ImaginAb is touting interim results from a phase II clinical trial of its IAB2M imaging agent for managing prostate cancer.
September 7, 2015
PET/MRI matches PET/CT for recurrent pelvic cancer
By Wayne Forrest
PET/MRI can provide high diagnostic performance for restaging gynecological cancer patients compared with FDG-PET/CT, with only slightly longer scan time and "markedly reduced" radiation exposure, according to a German study published online in the European Journal of Radiology.
September 3, 2015
2015 09 03 19 19 15 584 Grueneisen Clinical Image 450 20150904022927
Firm to develop Mo-99 without reactor
By AuntMinnie.com staff writers
California Science and Engineering of Irvine, CA, has announced that it plans to develop and produce molybdenum-99 (Mo-99) without a nuclear reactor.
September 2, 2015
Previous Page
Page 210 of 609
Next Page